Partnerships Apimeds Inc. (Korea, related party): license and supply arrangements for APITOX in licensed territories; Piramal Pharma Solutions (manufacturing of clinical trial material)
Indications
Knee osteoarthritis (OA) - approved in South Korea since 2003; US Phase 3 planned(Approved)
Multiple sclerosis (MS) - early research(Stage not disclosed)
Status note Apitoxin approved in South Korea for OA since 2003 (MFDA). Company plans its own US Phase III in knee OA (BLA path) after the Apimeds Korea Phase III (2018) was deemed inadequate by FDA. MS efforts refocused on early-stage work. BioBusiness separation (51% Lokahi distribution) pending under April 2026 settlement.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.